Klaus Nagels

Positions and relevant areas of responsibility

• since 2017 Chair of Healthcare Management and Health Services Research (University of Bayreuth)
• 2010 – 2016 Professor (W3) for Medical Management and Health Sciences (University of Bayreuth)
• 2009 – 2017 Accreditation as Expert Witness and full membership of the Expert Witness Institute (London, England)
• 2007 – 2008 Expert witness in international lawsuits, including damage litigations in biotechnology ("breach of contract", US$ 750 million) at the Supreme Court of Victoria, (Melbourne, Australia)
• 2005 – 2007 Head of Practice Group Life Science an der ESMT European School of Management and Technology (Berlin, Germany)
• 2007 Founding of Tiberius Transformation Consulting GmbH
• 1997 – 2002 Various management and leadership positions at Cap Gemini Consulting with offices in Frankfurt, London, Paris and Roland Berger Strategy
• Consultants.Consulting segments in connection with strategic and operational topics of the respective business models (strategy development, restructuring, organization, IT and digitization topics): International management and supervisory boards of biotechnological and pharmaceutical industrial companies, financial industry (banks, venture capital, private equity), owners of acute hospitals, university clinics, rehabilitation clinic groups, nursing home operators.Locations in Europe, USA, People's Republic of China.
• 1992 – 1997 Manager and department head in drug development of biotechnological preparations for cancer and metabolic diseases (prostate carcinoma, diabetes mellitus II, haematological diseases), parenteral depot systems for highly effective biotechnologically derived active substances such as LHRH-agonists and antagonists, human GLP-1, erythropoietin (EPO), comprehensive tasks in the economic evaluation of innovations and technology (NPV calculations, first pharmacoeconomic evaluation in connection with prostate cancer treatments)

Academic training and further qualifications

• 2014 Habilitation at the University of Bayreuth with a thesis on global diffusion of proton irradiation technology (Dr. rer. pol. habil.)
• 2014 Permission to practise as a pharmacist in the Swiss cantons of Zurich and Graubünden
• 2010 Approval as a pharmacist by the Federal Office of Public Health of Switzerland
• 1997 – 1998 Roland Berger Curriculum (Corporate Finance etc.), INSEAD, Fontainebleau, Brussels and Lisbon
• 1995 Doctorate at ETH Zurich (Dr. sc. nat.) with a dissertation on transdermal therapy systems.Award of the ETH Zurich Medal for an outstanding dissertation.
• 1989 – 1992 Doctoral studies, dissertation and assistant at the Pharmaceutical Institute of the ETH Zurich.Development of a patented manufacturing technology for transdermal drug delivery systems, in-depth studies in general and clinical pharmacology (Prof. Hanns Möhler) and pharmacokinetics (Prof. Heidi Wunderli). In the course of his doctoral studies, Drug Delivery Systems under Prof. Norman Mazer (Salt Lake City, Utah) and Prof. Dr. Joseph Robinson (Madison, Wisconsin) and medical studies (University of Düsseldorf)
• 1988 Approbation as a pharmacist
• 1986 DAAD scholarship and studies (ETH Zurich)
• 1983 – 1987 Study of pharmaceutical sciences (University of Bonn)
• 1981 – 1982 Medical service at the Bundeswehr, medical training program with distinction in Budel (Netherlands), Bad Zwischenahn, Leer (military ambulance service)

Priorieties

• Industrialization and transformation in the healthcare industry
• Development of business models in the context of digital healthcare
• Radiooncological and general oncological care issues
• Technology and innovation management